A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body

• Status: COMPLETED
• Trial end date: 2024-10-16

Summary

The main objective of this trial is to assess the effect of multiple oral doses of zongertinib on the pharmacokinetics of midazolam, omeprazole and repaglinide.

• Phase: PHASE1

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Midazolam; Omeprazole; repaglinide